| Literature DB >> 21586120 |
Ryuichi Kawamoto1, Yasuharu Tabara, Katsuhiko Kohara, Tetsuro Miki, Tomo Kusunoki, Shuzo Takayama, Masanori Abe, Tateaki Katoh, Nobuyuki Ohtsuka.
Abstract
BACKGROUND: There are few studies to demonstrate the associations between newly addressed lipid profiles and metabolic syndrome (MetS)-associated variables.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21586120 PMCID: PMC3118370 DOI: 10.1186/1476-511X-10-79
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Characteristics of subjects categorized by sex
| Characteristics | Men N = 614 | Women N = 779 | |
|---|---|---|---|
| Age (years) | 58 ± 14 | 60 ± 12 | 0.001 |
| Body mass index (kg/m2) | 23.3 ± 3.0 | 22.9 ± 3.2 | 0.027 |
| Smoking status {never/ex/light/heavy (%)} | 37.8/20.8/17.9/23.5 | 97.2/0.8/1.9/0.1 | <0.001 |
| Alcohol consumption {never/light/moderate/heavy (%)) | 12.2/29.5/34.7/23.6 | 60.1/33.4/5.9/0.6 | <0.001 |
| Systolic blood pressure (mmHg) | 135 ± 19 | 132 ± 22 | 0.005 |
| Diastolic blood pressure (mmHg) | 82 ± 11 | 78 ± 12 | <0.001 |
| Total cholesterol (mg/dL) | 191 ± 34 | 209 ± 33 | <0.001 |
| Triglycerides (mg/dL) | 97 (71-140) | 85 (63-115) | <0.001 |
| HDL cholesterol (mg/dL) | 58 ± 14 | 65 ± 15 | <0.001 |
| LDL cholesterol (mg/dL) | 109 ± 32 | 124 ± 30 | <0.001 |
| Non-HDL cholesterol (mg/dL) | 132 ± 34 | 143 ± 33 | <0.001 |
| Total cholesterol/HDL cholesterol ratio | 3.45 ± 1.01 | 3.35 ± 0.92 | 0.066 |
| Triglycerides/HDL cholesterol ratio | 1.67 (1.16-2.74) | 1.29 (0.89-1.97) | 0.001 |
| LDL cholesterol/HDL cholesterol ratio | 2.00 ± 0.81 | 2.02 ± 0.75 | 0.601 |
| eGFR | 83.9 ± 16.3 | 82.7 ± 16.5 | 0.183 |
| Cardiovascular disease, % | 5.7 | 3.9 | 0.124 |
HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate. Data presented are mean ± standard deviation. Data for triglycerides and triglycerides/HDL cholesterol ratio were skewed and were presented as median (interquartile range). Data for triglycerides and triglycerides/HDL cholesterol ratio were log-transformed for analysis. * Student's t-test or χ2 test.
Insulin resistance and prevalence of metabolic syndrome of subjects categorized by sex
| Characteristics | Men | Women | |
|---|---|---|---|
| Metabolic syndrome, % | 14.2 | 8.3 | 0.001 |
| Fasting blood glucose (mg/dL) | 94 (89-101) | 91 (86-97) | <0.001 |
| Immuno-reactive insulin (mU/mL) | 4.4 (2.8-7.2) | 5.6 (3.8-8.0) | <0.001 |
| HOMA-IR§ | 1.05 (0.64-1.81) | 1.27 (0.84-1.84) | <0.001 |
| Serum HMW adiponectin (μg/mL) | 3.20 (1.97-4.92) | 6.65 (4.42-9.64) | <0.001 |
HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high molecular weight. Data for fasting blood glucose, fasting insulin, HOMA-IR, and serum HMW adiponectin were skewed and presented as median (interquartile range) values. §HOMA-IR was calculated using the following formula; {fasting blood glucose (FBG) (mg/dL) X fasting insulin (mU/mL)}/405. Data for fasting blood glucose, immuno-reactive insulin, HOMA-IR, and serum HMW adiponectin were log-transformed for analysis. * Student's t-test or χ2 test.
Figure 1Synergistic effect of increased HOMA-IR (homeostasis model assessment of insulin resistance) and reduced serum HMW (high molecular weight) adiponectin. Mean accumulated number of the following MetS (metabolic syndrome) components: obesity, increased Blood pressure, impaired fasting glucose, dyslipidemia (hypertriglyceridemia or low high-density lipoprotein cholesterolemia). Study participants were divided into four groups (quartile) according to HOMA-IR and serum HMW adiponectin levels. Each quartile was calculated within sexes and then combined to eliminate any gender differences. Statistical significance was assessed by a general linear model for the following confounding factors: age, sex, BMI, smoking status, alcohol consumption, SBP, DBP, and eGFR.
Multiple linear regression analysis of the lipid measures with the number of MetS components, HOMA-IR and serum HMW adiponectin of subjects categorized by sex
| Characteristics | ||||||
|---|---|---|---|---|---|---|
| Number. of MetS components | HOMA-IR§ | Serum HMW adiponectin | ||||
| Men | Women | Men | Women | Men | Women | |
| N = 614 | N = 779 | N = 614 | N = 779 | N = 614 | N = 779 | |
| Triglycerides (mg/dL) | 0.337 (<0.001) | 0.266 (<0.001) | 0.237 (<0.001) | 0.231 (<0.001) | -0.232 (<0.001) | -0.237 (<0.001) |
| HDL cholesterol (mg/dL) | -0.193 (<0.001) | -0.121 (<0.001) | -0.175 (<0.001) | -0.122 (<0.001) | 0.218 (<0.001) | 0.329 (<0.001) |
| LDL cholesterol (mg/dL) | -0.021 (0.503) | 0.051 (0.048) | 0.091 (0.009) | 0.107 (0.001) | -0.126 (0.001) | -0.176 (0.001) |
| Non-HDL cholesterol (mg/dL) | 0.115 (<0.001) | 0.134 (<0.001) | 0.164 (<0.001) | 0.158 (<0.001) | -0.188 (<0.001) | -0.227 (<0.001) |
| Total cholesterol/HDL cholesterol ratio | 0.256 (<0.001) | 0.201 (<0.001) | 0.252 (<0.001) | 0.198 (<0.001) | -0.295 (<0.001) | -0.362 (<0.001) |
| Triglycerides/HDL cholesterol ratio | 0.354 (<0.001) | 0.257 (<0.001) | 0.258 (<0.001) | 0.228 (<0.001) | -0.270 (<0.001) | -0.315 (<0.001) |
| LDL cholesterol/HDL cholesterol ratio | 0.143 (<0.001) | 0.148 (<0.001) | 0.209 (<0.001) | 0.174 (<0.001) | -0.265 (<0.001) | -0.352 (<0.001) |
MetS, Metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high molecular weight; HDL, high-density lipoprotein; LDL, low-density lipoprotein. §HOMA-IR was calculated using the following formula; {fasting blood glucose (mg/dL) X immuno-reactive insulin (mU/mL)}/405. Adjusted for age were BMI, smoking status, alcohol consumption, SBP, DBP, and eGFR. Data for triglycerides, triglycerides/HDL cholesterol ratio, and HOMA-IR were skewed, and log-transformed for analysis.
Comparison of areas under the ROC curves (95% CI) for potential markers of insulin resistance of subjects categorized by sex
| Presence of MetS | HOMA-IR§ >1.98 | Serum HMW adiponectin <2.97 μg/mL | ||||
|---|---|---|---|---|---|---|
| Characteristics | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | |||
| Men, N = 614 | ||||||
| Triglycerides (mg/dL) | 0.81 (0.76-0.86) | <0.001 | 0.73 (0.68-0.78) | <0.001 | 0.67 (0.63-0.71) | <0.001 |
| HDL cholesterol (mg/dL) | 0.28 (0.22-0.34) | <0.001 | 0.31 (0.26-0.36) | <0.001 | 0.40 (0.35-0.44) | <0.001 |
| LDL cholesterol (mg/dL) | 0.56 (0.50-0.63) | <0.001 | 0.60 (0.54-0.65) | <0.001 | 0.51 (0.47-0.56) | 0.577 |
| Non-HDL cholesterol (mg/dL) | 0.68 (0.62-0.74) | <0.001 | 0.66 (0.61-0.71) | <0.001 | 0.56 (0.51-0.61) | 0.011 |
| Total cholesterol/HDL cholesterol ratio | 0.76 (0.70-0.81) | <0.001 | 0.73 (0.68-0.78) | <0.001 | 0.61 (0.56-0.65) | <0.001 |
| Triglycerides/HDL cholesterol ratio | 0.82 (0.77-0.87) | <0.001 | 0.75 (0.70-0.80) | <0.001 | 0.67 (0.63-0.71) | <0.001 |
| LDL-cholesterol/HDL-cholesterol ratio | 0.68 (0.62-0.74) | <0.001 | 0.69 (0.63-0.74) | <0.001 | 0.57 (0.53-0.62) | 0.002 |
| Women, N = 779 | ||||||
| Triglycerides (mg/dL) | 0.83 (0.77-0.89) | <0.001 | 0.68 (0.64-0.73) | <0.001 | 0.63 (0.56-0.70) | <0.001 |
| HDL cholesterol (mg/dL) | 0.25 (0.19-0.32) | <0.001 | 0.38 (0.29-0.39) | <0.001 | 0.28 (0.22-0.34) | <0.001 |
| LDL cholesterol (mg/dL) | 0.62 (0.54-0.69) | 0.021 | 0.60 (0.56-0.65) | <0.001 | 0.54 (0.47-0.62) | 0.218 |
| Non-HDL cholesterol (mg/dL) | 0.70 (0.63-0.78) | 0.457 | 0.64 (0.59-0.69) | <0.001 | 0.59 (0.52-0.66) | 0.014 |
| Total cholesterol/HDL cholesterol ratio | 0.78 (0.72-0.84) | <0.001 | 0.69 (0.65-0.74) | <0.001 | 0.70 (0.63-0.76) | <0.001 |
| Triglycerides/HDL cholesterol ratio | 0.84 (0.78-0.89) | <0.001 | 0.70 (0.65-0.74) | <0.001 | 0.69 (0.62-0.75) | <0.001 |
| LDL cholesterol/HDL cholesterol ratio | 0.74 (0.68-0.81) | <0.001 | 0.68 (0.63-0.72) | <0.001 | 0.68 (0.62-0.75) | <0.001 |
ROC, receiver operating characteristics; MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high molecular weight; AUC, area under ROC curve; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein. §HOMA-IR was calculated using the following formula; {fasting blood glucose (mg/dL) X immuno-reactive insulin (mU/mL)}/405. Insulin resistance was defined as values exceeding the fourth quartile of HOMA-IR, and less than the first quartile of serum HMW adiponectin, respectively.